Ottawa, ON - Patented Medicine Prices Review Board
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel has issued an Order relating to the medicine Soliris, manufactured and marketed in Canada by Alexion Pharmaceuticals Inc.
In 2017, the Hearing Panel issued a Decision and Order regarding the pricing of Soliris. The decision was judicially reviewed in 2019 and subsequently appealed to the Federal Court of Appeal. In 2021, following a decision of the Federal Court of Appeal, the matter was remitted back to the Board for redetermination.
The Hearing Panel has issued a final Order that the redetermination proceeding be discontinued, based on a joint request by the parties. The final Order outlines the terms for the proceeding to be discontinued.
Soliris is the first and only treatment for patients with Paroxysmal Nocturnal Hemoglobinuria - a rare and life-threatening blood disorder characterized by excessive destruction of red blood cells - and Atypical Hemolytic Uremic Syndrome, a rare and life-threatening genetic disorder characterized by blood clots in small vessels.
